top of page

Ascidian Therapeutics' CEO discusses today's collaboration with Roche on the company's RNA exon editing technology for neurological conditions

  • blonca9
  • Jun 18, 2024
  • 1 min read

Mike Ehlers describes how this $42M upfront and up to $1.8B in potential milestones deal is focused on neurological conditions, how RNA exon editing could be the right platform for this area of medicine, and why he thinks Roche is the right partner.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page